A sponge-like gold nanoparticle platform could deliver faster, more accurate, and less invasive ovarian cancer diagnostics.

InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology ...

Since many cancers don’t have symptoms early on, they may go unnoticed until they are at an advanced stage. But that is ...

SAN FRANCISCO, May 22, 2025 /PRNewswire/ -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a ...

A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...